07.28.21
Cerba Research was awarded a five-year contract for clinical central lab services from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
NIAID conducts and supports research to better understand, treat, and prevent infectious, immunologic, and allergic diseases. Findings from this research aim to advance vaccines, drugs, and diagnostic tools to better diagnose, prevent, and treat infectious diseases. Cerba Research will provide clinical laboratory screening and safety testing for NIAID-supported clinical trials within the infectious disease area.
“We are pleased to be recognized for our depth and breadth of central and specialty lab solutions across the globe to support NIAID. Through our innovative mindset, courageous people, and our work in vaccines and treatments in the field of infectious diseases, we understand the importance in bringing these to people. Hence, we are committed to supporting the NIAID’s clinical research initiatives to improve health,” said Mario Papillon, chief executive officer, Cerba Research.
NIAID conducts and supports research to better understand, treat, and prevent infectious, immunologic, and allergic diseases. Findings from this research aim to advance vaccines, drugs, and diagnostic tools to better diagnose, prevent, and treat infectious diseases. Cerba Research will provide clinical laboratory screening and safety testing for NIAID-supported clinical trials within the infectious disease area.
“We are pleased to be recognized for our depth and breadth of central and specialty lab solutions across the globe to support NIAID. Through our innovative mindset, courageous people, and our work in vaccines and treatments in the field of infectious diseases, we understand the importance in bringing these to people. Hence, we are committed to supporting the NIAID’s clinical research initiatives to improve health,” said Mario Papillon, chief executive officer, Cerba Research.
